105 related articles for article (PubMed ID: 1279974)
1. Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer.
Jikihara H; Terada N; Yamamoto R; Nishikawa Y; Tanizawa O; Matsumoto K; Terakawa N
Am J Obstet Gynecol; 1992 Jul; 167(1):207-11. PubMed ID: 1279974
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA).
Uchida M; Tsuboi H; Yamaji T; Murata N; Kohno T; Sugino E; Hibino S; Shimamura M; Oikawa T
Cancer Lett; 2000 Jun; 154(1):63-9. PubMed ID: 10799740
[TBL] [Abstract][Full Text] [Related]
3. Histochemical evaluation of angiogenesis in endometrial adenocarcinoma.
Puisoru M; Fatu C; Fatu IC
Ann Anat; 2006 May; 188(3):255-9. PubMed ID: 16711164
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors.
Fujimoto J; Hosoda S; Fujita H; Okada H
Invasion Metastasis; 1989; 9(5):269-77. PubMed ID: 2475453
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.
Giavazzi R; Giuliani R; Coltrini D; Bani MR; Ferri C; Sennino B; Tosatti MP; Stoppacciaro A; Presta M
Cancer Res; 2001 Jan; 61(1):309-17. PubMed ID: 11196179
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogenic compounds inhibit estrogen-induced expression of fibroblast growth factor family (FGF-1, 2, and 4) mRNA in well-differentiated endometrial cancer cells.
Fujimoto J; Hori M; Ichigo S; Tamaya T
Eur J Gynaecol Oncol; 1997; 18(6):497-501. PubMed ID: 9443020
[TBL] [Abstract][Full Text] [Related]
7. Angiostatic activities of medroxyprogesterone acetate and its analogues.
Yamamoto T; Terada N; Nishizawa Y; Petrow V
Int J Cancer; 1994 Feb; 56(3):393-9. PubMed ID: 7508892
[TBL] [Abstract][Full Text] [Related]
8. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer.
Ribatti D; Finato N; Crivellato E; Marzullo A; Mangieri D; Nico B; Vacca A; Beltrami CA
Am J Obstet Gynecol; 2005 Dec; 193(6):1961-5. PubMed ID: 16325597
[TBL] [Abstract][Full Text] [Related]
9. The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia.
Abulafia O; Triest WE; Adcock JT; Sherer DM
Gynecol Oncol; 1999 Feb; 72(2):193-8. PubMed ID: 10021300
[TBL] [Abstract][Full Text] [Related]
10. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.
Presta M; Rusnati M; Belleri M; Morbidelli L; Ziche M; Ribatti D
Cancer Res; 1999 May; 59(10):2417-24. PubMed ID: 10344752
[TBL] [Abstract][Full Text] [Related]
11. Expression of interferon-gamma-inducible protein 10 related to angiogenesis in uterine endometrial cancers.
Sato E; Fujimoto J; Tamaya T
Oncology; 2007; 73(3-4):246-51. PubMed ID: 18424889
[TBL] [Abstract][Full Text] [Related]
12. The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate.
Horbelt DV; Delmore JE; Parmley TH; Roberts DK; Walker N
Hum Pathol; 1996 Jan; 27(1):9-14. PubMed ID: 8543319
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and Bcl-2 protein expression in patients with endometrial carcinoma.
Mazurek A; Pierzynski P; Niklinska W; Chyczewski L; Laudanski T
Neoplasma; 2002; 49(3):149-54. PubMed ID: 12097999
[TBL] [Abstract][Full Text] [Related]
14. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro.
Ueda M; Fujii H; Yoshizawa K; Abe F; Ueki M
Jpn J Cancer Res; 1996 May; 87(5):524-33. PubMed ID: 8641991
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.
Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ
Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer.
Mazurek A; Pierzyński P; Kuć P; Kopinski P; Terlikowski S; Niklińska W; Trojan J; Laudański T
Neoplasma; 2004; 51(3):193-7. PubMed ID: 15254672
[TBL] [Abstract][Full Text] [Related]
17. Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells.
Boostanfar R; Amezcua CA; Tourgeman DE; Roy S; Felix JC; Stanczyk FZ
Fertil Steril; 2003 Jan; 79(1):223-5. PubMed ID: 12524096
[No Abstract] [Full Text] [Related]
18. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells.
Lockwood CJ
Am J Obstet Gynecol; 2001 Apr; 184(5):798-804; discussion 804-5. PubMed ID: 11303186
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells.
Ashino-Fuse H; Takano Y; Oikawa T; Shimamura M; Iwaguchi T
Int J Cancer; 1989 Nov; 44(5):859-64. PubMed ID: 2479607
[TBL] [Abstract][Full Text] [Related]
20. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
